NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis $0.33 0.00 (0.00%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$0.33▼$0.3450-Day Range$0.32▼$0.4452-Week Range$0.25▼$0.88Volume324,755 shsAverage Volume611,081 shsMarket Capitalization$42.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Clene alerts: Email Address Clene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,885.3% Upside$6.50 Price TargetShort InterestHealthy0.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$17,535 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.34) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector297th out of 896 stocksPharmaceutical Preparations Industry135th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClene has only been the subject of 2 research reports in the past 90 days.Read more about Clene's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Clene have been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 44.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 2.8 News and Social Media Coverage News SentimentClene has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.Search Interest9 people have searched for CLNN on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Clene to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,535.00 in company stock.Percentage Held by Insiders25.10% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.28% of the stock of Clene is held by institutions.Read more about Clene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Clene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Clene Stock (NASDAQ:CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More CLNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLNN Stock News HeadlinesJune 24, 2024 | globenewswire.comClene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual ConferenceJune 21, 2024 | globenewswire.comClene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett SyndromeJuly 5, 2024 | Golden Crest (Ad)Urgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.June 18, 2024 | globenewswire.comClene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS MeetingMay 28, 2024 | globenewswire.comClene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)May 24, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative DiseasesMay 23, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For CleneMay 14, 2024 | finance.yahoo.comClene to Present at Upcoming May ConferencesJuly 5, 2024 | Golden Crest (Ad)Urgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 14, 2024 | globenewswire.comClene to Present at Upcoming May ConferencesMay 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)May 10, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation HighlightsMay 9, 2024 | finance.yahoo.comClene First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | finanznachrichten.deClene Inc.: Clene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)May 8, 2024 | investorplace.comCLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comClene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 1, 2024 | finance.yahoo.comIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob EtheringtonApril 23, 2024 | finance.yahoo.comBullish Clene Insiders Loaded Up On US$9.58m Of StockApril 17, 2024 | benzinga.comThe Analyst Verdict: Clene In The Eyes Of 5 ExpertsApril 16, 2024 | msn.comClene stock rallies 52% post-market on MS drug dataApril 16, 2024 | globenewswire.comEvidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual MeetingMarch 27, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MSMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | finance.yahoo.comIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob EtheringtonMarch 17, 2024 | morningstar.comClene Inc Ordinary SharesMarch 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market DynamicsSee More Headlines Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/04/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,885.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,500,000.00 Net Margins-7,873.23% Pretax Margin-7,873.23% Return on Equity-224.28% Return on Assets-60.21% Debt Debt-to-Equity Ratio1.66 Current Ratio1.23 Quick Ratio1.22 Sales & Book Value Annual Sales$650,000.00 Price / Sales64.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.27Miscellaneous Outstanding Shares128,430,000Free Float96,197,000Market Cap$42.05 million OptionableOptionable Beta0.46 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Robert Etherington MBA (Age 57)CEO, President & Director Comp: $1.06MMr. Morgan R. Brown CPA (Age 56)M.B.A., Chief Financial Officer Comp: $584.88kMr. Mark G. Mortenson ESQ. (Age 66)Chief Science Officer Comp: $729.92kMr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryMr. Michael T. HotchkinChief Development OfficerMs. Mary Anne McneilHead of Human ResourcesDr. Benjamin M. Greenberg M.D.M.H.S., Head of MedicalMore ExecutivesKey CompetitorsAcrivon TherapeuticsNASDAQ:ACRVImmutepNASDAQ:IMMPAbeona TherapeuticsNASDAQ:ABEORezoluteNASDAQ:RZLTVentyx BiosciencesNASDAQ:VTYXView All CompetitorsInsiders & InstitutionsCVI Holdings LLCSold 111,200 shares on 5/7/2024Ownership: 0.000%General Resonance LlcSold 13,000 sharesTotal: $5,460.00 ($0.42/share)General Resonance LlcSold 10,000 sharesTotal: $3,300.00 ($0.33/share)General Resonance LlcSold 22,500 sharesTotal: $8,775.00 ($0.39/share)David J MatlinBought 250,002 shares on 11/10/2023Total: $102,500.82 ($0.41/share)View All Insider TransactionsView All Institutional Transactions CLNN Stock Analysis - Frequently Asked Questions Should I buy or sell Clene stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks. What is Clene's stock price target for 2024? 4 brokerages have issued twelve-month price objectives for Clene's shares. Their CLNN share price targets range from $4.00 to $10.00. On average, they predict the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 1,885.3% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts. How have CLNN shares performed in 2024? Clene's stock was trading at $0.2966 at the beginning of the year. Since then, CLNN shares have increased by 10.4% and is now trading at $0.3274. View the best growth stocks for 2024 here. Are investors shorting Clene? Clene saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 333,400 shares, a decline of 44.1% from the May 31st total of 596,500 shares. Based on an average daily volume of 866,000 shares, the days-to-cover ratio is currently 0.4 days. View Clene's Short Interest. When is Clene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CLNN earnings forecast. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Clene had a negative trailing twelve-month return on equity of 224.28% and a negative net margin of 7,873.23%. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLNN) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredGet in before Reddit doesRobinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.